Proteomedix announces grant of U.S. patent on Proclarix®

Zurich-Schlieren, Switzerland, July 05, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, is pleased to announce that the United States Patent and Trademark Office granted to the company U.S. Patent No. 11,320,435, titled “Method of detecting proteins in human samples and uses of such methods” that covers Proteomedix’ lead product Proclarix^®.

“We are extremely pleased about the grant of this patent in the U.S. as it further validates the potential of Proclarix, strengthens our intellectual property position, and highlights our commitment to innovation of biomarkers for prostate cancer diagnosis and prognosis,” said Ralph Schiess, CSO and co-founder of Proteomedix.

The granted patent demonstrates the company’s strong intellectual property position in protein biomarker technology in the US (in addition to other markets), and complements the existing patent portfolio covering the method and cancer-specific biomarkers that is also granted across multiple markets.

The granted patents and published studies further validate the potential of Proclarix and support the company’s ongoing investigator-led observational studies evaluating the impact of the IVD-test on improving prostate cancer diagnosis and patient management.